Spotlight
Clinical
CME/CE
Dr. Chughtai discusses new pilot study on Rezum treatment for BPH
“We found that the adverse event rates have dropped dramatically, to about a third of what it was reported in the pivotal trial, but at the same time still had the same net benefits in terms of efficacy when it comes to Q max, symptomatic improvement, as well as PVR," said Bilal Chughtai, MD.
In this video, Bilal Chughtai, MD, an associate professor of Urology at Weill Cornell Medical College, discusses the background and findings of his recent paper, "Pilot study of ‘less is more’ Rezum for treatment of BPH."
Related Videos
